NCT00061646终止2 期
A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Abbott
- 入组人数
- 25
- 试验地点
- 8
- 主要终点
- Progression free survival
研究概览
简要总结
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Progression free survival
时间窗: One year
次要结局
- Overall survival(One year)
- Response rate(One year)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone SystemBone CancerBone MetastasesPainNCT01085565InSightec50
招募中
2 期
EUS-RFA PANCARDINAL-1 TrialPancreatic Ductal Adenocarcinoma (PDAC)NCT04990609The University of Texas Health Science Center, Houston60
招募中
2 期
Pembrolizumab Plus Radiotherapy for Advanced Renal CancerClear-cell Metastatic Renal Cell CarcinomaNCT05567588Nanfang Hospital, Southern Medical University66
尚未招募
2 期
eoadjuvant Short course radiotherapy in esophageal carcinomaCTRI/2020/12/029851AIIMS Rishikesh
已完成
2 期
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerTriple Negative Breast CancerBreast CancerNCT05112536G1 Therapeutics, Inc.24